Publication & Citation Trends
Publications
12 total
Discovery and Pharmacokinetic and Pharmacological Properties of the Potent and Selective MET Kinase Inhibitor 1-{6-[6-(4-Fluorophenyl)-[1,2,4]triazolo[4,3-<i>b</i>]pyridazin-3-ylsulfanyl]benzothiazol-2-yl}-3-(2-morpholin-4-ylethyl)urea (SAR125844) PDF
Cited by 29
OpenAlex
The Selective Intravenous Inhibitor of the MET Tyrosine Kinase SAR125844 Inhibits Tumor Growth in <i>MET</i> -Amplified Cancer PDF
Cited by 28
OpenAlex
Abstract 4648: In vitro characterization of spiro-oxindole-based modulators of the MDM2-p53 interaction and their interspecies selectivity.
Cited by 1
OpenAlex
Abstract 845: <i>In vitro</i> and <i>in vivo</i> pharmacology of SAR125844, a potent and selective intravenous MET kinase inhibitor undergoing Phase I clinical trial
Cited by 1
OpenAlex
Abstract 845:In vitroandin vivopharmacology of SAR125844, a potent and selective intravenous MET kinase inhibitor undergoing Phase I clinical trial
Cited by 1
Semantic Scholar
287 POSTER Characterizati on of alvocidib (flavopiridol)-mediated inhibition of CDK enzyme activity and the down-regulation of gene transcription
Cited by 0
OpenAlex
Research Topics
Liver physiology and pathology
(7)
Cancer, Hypoxia, and Metabolism
(3)
Estrogen and related hormone effects
(3)
Cancer-related Molecular Pathways
(2)
Bioactive Compounds and Antitumor Agents
(2)
Affiliations
Centre National de la Recherche Scientifique
Université Paris Cité
Sanofi (France)
Euro-Centrum